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Abstract
Background: Carbamoyl phosphate synthetase 1 (CPS1) is a liver-specific enzyme with
the lowest enzymatic rate, which determines the overall rate of the other reactions in
the pathway that converts ammonia to carbamoyl phosphate in the first step of the urea
cycle. Carbamoyl phosphate synthetase 1 deficiency (CPS1D), which usually presents
as lethal hyperammonemia, is a rare autosomal recessive hereditary disease.
Case: We report a case of a two-day-old female neonate with lethal hyperammonemia.
The newborn infant was presented with hyperammonemia (34.7 𝜇g/ml; reference
range 1.1–1.9). In Plasma amino acid analysis, there was a significant elevated levels of
alanine (3,004 𝜇mol/L; reference range, 236–410 𝜇mol/L), glutamine (2,256 𝜇mol/L;
reference range, 20–107 𝜇mol/L), asparagine (126 𝜇mol/L; reference range, 30–69
𝜇mol/L), glutamic acid (356 𝜇mol/L; reference range, 14–192 𝜇mol/L), aspartic acid
(123 𝜇mol/L; reference range, 0–24 𝜇mol/L), and lysine (342 𝜇mol/L; reference range,
114–269 𝜇mol/L). We cannot diagnose the urea cycle disorder (UCD) CPS1D properly
only based on the quantity of biochemical intermediary metabolites to exclude other
UCDs with similar symptoms. Following next generation sequencing determined one
homozygous mutation in CPS1 gene and also this mutation was determined in her
parents. The identified mutation was c.2758G > C; p.Asp920His, in the 23 exon of
CPS1. This novel homozygous mutation had not been reported previously.
Conclusion:We applied whole exome sequencing successfully to diagnose the patient
with CPS1D in a clinical setting. This result supports the clinical applicability of whole
exome sequencing for cost-effective molecular diagnosis of UCDs.
Key words: CPS1 deficiency, Hyperammonemia, Urea cycle disorder, Whole exome
sequencing.
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1. Introduction
The urea cycle is the primary function of the
liver that is highly conserved in all mammalian
species, this process Converting toxic ammonium
into the less toxic urea(1, 2). There are six enzymes
in urea cycle, including Carbamoyl phosphate
synthetase 1 (CPS1), N-acetylglutamate synthase
(NAGS), ornithine carbamoyl transferase (OTC),
arginosuccinate synthetase, arginosuccinate lyase,
and arginase. High ammonium concentration in the
blood caused by the deficiency in any of these
enzymes can have harmful effects as serious as
anorexia, central nervous system dysfunction, brain
damage, lethargy, coma, and even death (3, 4).
CPS1 converts ammonia to carbamoyl phosphate
in the first step of the urea cycle (5). The incidence
of Carbamoyl phosphate synthetase 1 deficiency
(CPS1D) was reported to be 1/62000 in the United
States (5), 1/539000 in Finland (6), and 1/800000
in Japan (7). CPS1D has been classified into two
different clinical phenotypes based on the activity
level of the CPS1 enzyme, clinical manifestations,
and the age of onset. These two groups included
Neonatal onset and late onset and the first one
that manifests clinically within the first few days
of life is Neonatal onset CPS1D. The affected
infant was characterized by refusal to feed, hypo-
tonia, lethargy, convulsions, hypothermia, vomiting,
coma, and even death (8).
By contrast, there are less severe clinical mani-
festations associated with later onset CPS1D. CPS1,
which is located on 2q35, is a large gene, spanning
over 120 kb, consisting of over 38 coding exons,
which is about 4500 coding nucleotides (9).
As described in the Leiden Open Variation
Database (LOVD, http://www.LOVD.nl/CPS1) and
the Human Gene Mutation Database (HGMD, http:
//www.hgmd.org/), there are More than 240 CPS1
pathogenic variations that are reported to be
enormously distributed among the coding exons
in CPS1 pathogenic variants. Just about 10% of
the identified pathogenic variants take place in
unrelated cases, predominantly affecting CpG din-
ucleotides, further complicating diagnosis due to
the “private” nature of such pathogenic variants
(10).
Previously, the relationship between mutation in
the CPS1 and homocysteine has been reported in
women, and homocysteine is found frequently in
women with RPL. Inborn metabolic disorders have
been considered as a harmful factor for mother,
embryo, and the pregnancy (11, 12). However, an
increasing number of evidence propose that fetal
inborn metabolic disorders can be associated with
serious medical problems including fetal cardiomy-
opathy, structural defects of brain, isolated ascites
or hydrops fetalis, congenital malformation, and
fetal death (13).
This article aims to highlight the consequences
of inborn metabolic disease of the fetus on the
pregnancy outcome and to suggest a metabolic
work up for cases with clinical problems relating
to pregnancy because this family has experienced
three pregnancy losses.
2. Case Presentation
We report a two-day-old female neonate with
symptoms including poor feeding, flatulence,
and lethargy that started a day after her birth.
Her weight at birth was 3010 gr, and the patient
had no facial dysmorphism or other phenotypic
abnormalities at birth. At admission, primary
physiological neurologic reflex was observed.
Her blood tests showed hyperammonemia (34.7
ug/ml; reference range, 1.1–1.9). Plasma amino
acid analysis revealed markedly elevated levels of
alanine (3,004 𝜇mol/L; reference range, 236-410
𝜇mol/L), glutamine (2,256 𝜇mol/L; reference range,
20–107 𝜇mol/L), asparagine (126 𝜇mol/L; reference
range, 30–69 𝜇mol/L), glutamic acid (356 𝜇mol/L;
reference range, 14–192 𝜇mol/L), aspartic acid (123
𝜇mol/L; reference range, 0–24 𝜇mol/L) and lysine
(342 𝜇mol/L; reference range, 114–269 𝜇mol/L).
Collectively, these results suggested a urea cycle
disorder (UCD).
2.1. Genetic test
After genetic counseling and collection of the
parents’ informed consents cytogenetic analysis
was performed using peripheral blood of the
patient and the parent, based on G-banding
and standard phytohemagglutinin-stimulated lym-
phocyte. Cytogenetic analysis revealed a nor-
mal karyotype. We performed Single Nucleotide
Polymorphism (SNP) array using Illumina Human
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CytoSNP-12 V2.1 bead-chip array. Subsequent
analyses using Genome Studio V2010.2 were
performed to analyze the generated data. We
defined almost 2 Mb deletion region on chr 2q37.
The result from analyses revealed that the genes
presented in deleted sites are not correspondent
to patient symptoms. Afterward, we performed
a whole exome genome sequencing based on
next generation sequencing (NGS; Illumina plat-
form). For aligning sequences, we used GATK,
BWA, and ANNOVAR software to identify vari-
ants and annotating, respectively. After the filtra-
tion of all identified variants, we found a novel
missense c. 2758G> C mutation in exon 23 of
CPS1 at amino acid position 920 (p. Asp920His).
At the end, we used the Sanger sequencing
to confirm that the mutation was in the patient
(homozygous). The mutation was checked in her
parents and other family members too (Figure
1).
Figure 1. (A) Pedigree of family with individuals affected by Carbamoyl phosphate synthetase 1 deficiency (CPS1D). Segregation
of mutation in the family with the mutation allele is shown by –, and wild type is shown by +. (B) SNP array profile of the case; 2
Mb delition region on chr 2q37. (C) Sanger sequence of the CPS1 gene revealed c.2758G > C mutation.
3. Discussion
CPS1 converts ammonia to carbamoyl phos-
phate in the first step of the urea cycle and CPS1
gene, which is located on 2q35, is a large gene,
spanning over 120 kb. This gene has 13 transcripts
and consisting of over 38 coding exons which is
about 4500 coding nucleotides (8, 14). CPS1D is
a rare autosomal recessive disease and can be
Lethal hyperammonemia agent. this is a severe
type of UCD. Hypothermia, anorexia, vomiting,
convulsions, and coma are some of the clinical
symptoms of severe CPS1D (15). The most seri-
ous complication of CPS1D is Irreversible damage
to the central nervous system, which is closely
related to the long-term prognosis of neonates
(16). Early identification of these signs is vital (17).
The one mutation we report herein is located on
exon 23 (c.2758G > C; p.Asp920His). This novel
homozygous mutations were inherited from our
patient’s parents, whereas the exact mechanism of
dysfunction of humanCPS1 caused by thismutation
remains unclear. Severe hyperammonemia is the
usual presentation of the neonatal onset type
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and early death often occurs in these cases.
Relationship between mutation in the CPS1 and
homocysteine has been proved in womenwith RPL
and given that heterozygous individuals have no
symptoms of homocysteine, further studies are
needed to investigate the relationship between
CPS1 and abortion (11, 12). Recent study as well as
molecular analysis have revealed that mutations in
CPS1 gene cannot cause abortion. According to
this fact that CPS1 pathogenic variation was found
only in 4-6 and considering the healthy persons
identifying with 3-4, the aborted fetus in 5-1 cannot
be as a result of homozygous mutation in CPS1
gene because its mother doesn’t carrying for this
mutation. We emphasize the importance of collect-
ing and storing of biological samples. Biochemical
assays and gene mutation analysis are helpful in
making the diagnosis. Prenatal diagnosis is also
available in UCDs. Molecular diagnosis of CPS1D
can be hampered by the large size of the CPS1
gene. Genetic analysis is a key element in diagnos-
ing CPS1D and for performing counseling, prenatal
diagnosis, and eventually (10), for future procedures
of disease-free embryo selection. Despite the fact
that prenatal CPS1D diagnosis has been introduced
in other populations, there is currently no prenatal
diagnosis test in Iran. Today, Development of NGS
technologies promising researcher to generate
large amounts of sequence data at a lower cost
and with less attempt, provided new possibilities
for diagnostic pathogenic variant screening (18).
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